Advertisement
U.S. markets close in 4 hours 20 minutes

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7700-0.1100 (-2.84%)
As of 11:32AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close3.8800
Open3.8800
Bid3.6000 x 800
Ask3.6800 x 1000
Day's Range3.6867 - 3.7700
52 Week Range2.5500 - 5.9900
Volume1,680
Avg. Volume5,318
Market Cap5.808M
Beta (5Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)-2.9000
Earnings DateMar 21, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xenetic Biosciences, Inc.
    Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more